News

Erasca Announces FDA Clearance of UCLA Developed Drug

UCLA Researchers David Nathanson, Ph.D., Michael Jung, Ph.D., and Timothy Cloughesy, M.D. developed ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of recurrent glioblastoma multiforme (rGBM). The company Erasca licensed ERAS-801 from Katmai Pharmaceuticals, Inc. and received FDA clearance.

UCLA ranked No. 1 public university by U.S. News & World Report for fourth straight year

UCLA once again sits atop the list of the nation’s public universities in U.S. News & World Report’s annual “Best Colleges,” which was published today.

This is the fourth consecutive year UCLA has captured this honor.

Read More here:  https://newsroom.ucla.edu/releases/ucla-no-1-us-public-university-us-news-world-report-2021